Welcome to our dedicated page for ONCOLYTICS BIOTECH SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncolytics Biotech filings document a clinical-stage oncology company developing pelareorep and reporting material events through Form 8-K disclosures. Recent filings cover pelareorep study updates in metastatic colorectal cancer and squamous cell anal carcinoma, FDA-related development communications, translational data presented from GOBLET and AWARE-1, and incorporation of certain exhibits into a Form F-3 registration statement.
The company's regulatory record also documents capital-structure matters, including Nasdaq-listed ONCY common stock and an open-market sale agreement, as well as corporate-status changes tied to its completed continuance and domestication from Canadian jurisdictions to Nevada. These filings describe governance approvals, registered securities, financing arrangements, and oncology development disclosures for the issuer.
Oncolytics Biotech Inc. is shifting its development strategy to focus on registrational and registration-enabling studies of its immunotherapy pelareorep in squamous cell anal cancer and metastatic colorectal cancer. The company has concluded enrollment in its GOBLET gastrointestinal cancer study, having obtained sufficient clinical and translational data to guide next steps.
Oncolytics plans a mid-April meeting with the U.S. Food and Drug Administration to align on a single-arm registrational study in second-line and later anal cancer, which it believes could enroll well under 100 patients. To concentrate resources and manage spending, the company will wind down GOBLET by stopping new enrollment in the metastatic pancreatic cancer cohorts at approximately 20 patients per arm while continuing to follow existing participants. Management states it has sufficient cash on hand to execute near-term milestones and expects to avoid immediate material dilution.
Oncolytics Biotech Inc. CEO and director Kelly Jared reported buying additional common shares in the open market. On February 11, 2026, he purchased 5,600 common shares at a weighted average price of $0.836, and on February 12, 2026, he bought 29,500 common shares at a weighted average price of $0.842.
The filing notes these were executed through multiple trades at prices ranging from $0.820 to $0.856. After these transactions, Jared directly owns 109,000 Oncolytics Biotech common shares.
Oncolytics Biotech Inc. filed a Form 4 showing that its Chief Financial Officer, Kirk Look, made an open-market purchase of company stock. On February 12, 2026, he bought 12,000 common shares at a price of $0.842 per share. After this transaction, he directly beneficially owned 287,515 common shares of Oncolytics Biotech. The filing classifies this as a direct ownership position, reflecting additional personal investment by the company’s senior financial officer.
Oncolytics Biotech Inc. director Wayne Pisano reported an open-market purchase of 30,000 common shares of ONCY on February 12, 2026. The shares were bought at a weighted average price of $0.8446 per share, in multiple trades ranging from $0.83 to $0.85.
Following this transaction, Pisano directly holds 492,414 common shares of Oncolytics Biotech Inc. The filing notes that detailed trade-by-trade pricing information is available upon request for investors or regulators who want to review each individual purchase within the reported price range.
Oncolytics Biotech Inc. Chief Medical Officer Thomas Charles Heineman reported an open-market purchase of 12,132 common shares on February 12, 2026 at a price of $0.827 per share. Following this transaction, he directly owns 282,818 Oncolytics Biotech common shares.
Oncolytics Biotech Inc. director Deborah Margaret Brown bought additional company shares. On February 12, 2026, she made an open-market purchase of 25,000 common shares at a weighted average price of $0.8496 per share. After this transaction, she directly owns 109,851 common shares of Oncolytics Biotech Inc.
The filing notes that the purchase price reflects multiple trades executed within a range from $0.835 to $0.85 per share, and detailed trade breakdowns are available upon request.
Oncolytics Biotech Inc. VP of Product Development Allison Hagerman bought 10,000 common shares in the open market on February 12, 2026 at $0.8298 per share. After this purchase, she directly owned a total of 115,059 common shares of the company.
Oncolytics Biotech director Bernd R. Seizinger bought additional common shares in two open-market transactions. On February 11, 2026, he purchased 60,000 common shares at $0.8265 per share. On February 12, 2026, he bought another 40,000 common shares at $0.8466 per share.
After these transactions, Seizinger directly owns 566,991 common shares of Oncolytics Biotech Inc. The filing classifies both trades under transaction code "P," indicating purchases in the open market or private transactions.
Oncolytics Biotech Inc.'s Chief Business Officer, Andrew Aromando, bought additional company stock in the open market. On February 11, 2026, he purchased 29,600 common shares of Oncolytics Biotech at a weighted average price of $0.8587 per share, increasing his direct holdings to 55,100 common shares.
Oncolytics Biotech Inc. director Patricia S. Andrews bought 35,400 common shares in open-market transactions on February 12, 2026 at a weighted average price of $0.8557 per share. Following these purchases, she directly owns 78,128 common shares of the company.
The filing notes the trades were executed in multiple lots at prices ranging from $0.8483 to $0.86 per share, with the weighted average reported. Andrews has indicated she can provide full trade-by-trade pricing details to the company, its shareholders, or the SEC staff upon request.